- Home
- RLYB
RLYB
Rallybio Corporation
as 05-09-2025 4:00pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 13.3M | IPO Year: | 2021 |
| Target Price: | $15.00 | AVG Volume (30 days): | 86.0K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $2.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $848,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Business Wire
11 days ago
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
MT Newswires
a month ago
Evercore ISI Downgrades Rallybio to In Line From Outperform
Zacks
a month ago
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
MT Newswires
a month ago
HC Wainwright Downgrades Rallybio to Neutral From Buy
Clinical Trials Arena
a month ago
Rallybio drops drug for rare maternal disorder following Phase II fail
MT Newswires
a month ago
Rallybio Terminates RLYB212 Development for Rare Immune Disorder; Shares Fall
Business Wire
a month ago
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.